Mallinckrodt adds to executive leadership team

DUBLIN — Mallinckrodt last week announced that Gary Phillips, MD, currently the company's senior vice president and chief strategy office, has been named senior vice president and president of the company's autoimmune and rare disease business. The company also announced that Ray Furey, previously a senior vice president and chief compliance officer at Questcor Pharmaceuticals, was named senior vice president and the chief compliance officer at Mallinckrodt.



Phillips will take responsibility for the Acthar franchise and all of its sales, support and service initiatives. Furey's relationship will include reporting to the Mallinckrodt board of directors. Both will serve on the company's executive committee and will report directly to Mark Trudeau, the company's CEO.



“I look forward to working closely with Gary and Ray as we create a diversified, high-growth specialty pharmaceuticals company, with significantly increased scale, revenues, profitability and cash flow,” said Mark Trudeau, president and CEO of Mallinckrodt. “Since joining Mallinckrodt last year, Gary has brought focus to our growth strategy and energized our BD&L activities. Gary was one of the key architects of the Questcor transaction, and we are confident that he will achieve strong revenue and profit growth as we successfully expand the business into new indications. Ray is joining our team after more than two decades in the pharmaceutical industry. He has tremendous expertise and direct experience in compliance at leading global pharmaceutical companies. We are looking forward to having him as part of the Executive Committee and to the strong contributions he will provide to our expanded business.”



A search is underway for the chief strategy officer position, the company stated.